175 related articles for article (PubMed ID: 1676918)
1. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.
Salmon SE; Dalton WS; Grogan TM; Plezia P; Lehnert M; Roe DJ; Miller TP
Blood; 1991 Jul; 78(1):44-50. PubMed ID: 1676918
[TBL] [Abstract][Full Text] [Related]
2. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Dalton WS; Grogan TM; Meltzer PS; Scheper RJ; Durie BG; Taylor CW; Miller TP; Salmon SE
J Clin Oncol; 1989 Apr; 7(4):415-24. PubMed ID: 2564428
[TBL] [Abstract][Full Text] [Related]
3. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study.
Dalton WS; Crowley JJ; Salmon SS; Grogan TM; Laufman LR; Weiss GR; Bonnet JD
Cancer; 1995 Feb; 75(3):815-20. PubMed ID: 7828131
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
5. Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells.
Wyler B; Shao Y; Schneider E; Cianfriglia M; Scheper RJ; Frey BM; Gieseler F; Schmid L; Twentyman PR; Lehnert M
Br J Haematol; 1997 Apr; 97(1):65-75. PubMed ID: 9136943
[TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model.
Lehnert M; Dalton WS; Roe D; Emerson S; Salmon SE
Blood; 1991 Jan; 77(2):348-54. PubMed ID: 1670760
[TBL] [Abstract][Full Text] [Related]
7. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
8. Reversal of drug-resistance in multiple myeloma with verapamil.
Durie BG; Dalton WS
Br J Haematol; 1988 Feb; 68(2):203-6. PubMed ID: 3348977
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).
Sonneveld P; Suciu S; Weijermans P; Beksac M; Neuwirtova R; Solbu G; Lokhorst H; van der Lelie J; Dohner H; Gerhartz H; Segeren CM; Willemze R; Lowenberg B; ; ;
Br J Haematol; 2001 Dec; 115(4):895-902. PubMed ID: 11843823
[TBL] [Abstract][Full Text] [Related]
10. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells.
Sonneveld P; Schoester M; de Leeuw K
J Clin Oncol; 1994 Aug; 12(8):1584-91. PubMed ID: 7518859
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy.
Grogan TM; Spier CM; Salmon SE; Matzner M; Rybski J; Weinstein RS; Scheper RJ; Dalton WS
Blood; 1993 Jan; 81(2):490-5. PubMed ID: 8093668
[TBL] [Abstract][Full Text] [Related]
12. The role of P-glycoprotein in drug-resistant hematologic malignancies.
Dalton WS; Grogan TM; Miller TP
Cancer Treat Res; 1991; 57():187-208. PubMed ID: 1686717
[No Abstract] [Full Text] [Related]
13. VAD-cyclosporine therapy for VAD-resistant multiple myeloma.
Weber D; Dimopoulos M; Sinicrope F; Alexanian R
Leuk Lymphoma; 1995 Sep; 19(1-2):159-63. PubMed ID: 8574163
[TBL] [Abstract][Full Text] [Related]
14. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON.
Sonneveld P; Durie BG; Lokhorst HM; Marie JP; Solbu G; Suciu S; Zittoun R; Löwenberg B; Nooter K
Lancet; 1992 Aug; 340(8814):255-9. PubMed ID: 1353189
[TBL] [Abstract][Full Text] [Related]
15. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Jonsson B; Nilsson K; Nygren P; Larsson R
Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
[TBL] [Abstract][Full Text] [Related]
16. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma.
Schwarzenbach H
Med Oncol; 2002; 19(2):87-104. PubMed ID: 12180485
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression.
Müller MR; Lennartz K; Boogen C; Nowrousian MR; Rajewsky MF; Seeber S
Ann Hematol; 1992 Nov; 65(5):206-12. PubMed ID: 1360820
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.
Miller TP; Grogan TM; Dalton WS; Spier CM; Scheper RJ; Salmon SE
J Clin Oncol; 1991 Jan; 9(1):17-24. PubMed ID: 1670642
[TBL] [Abstract][Full Text] [Related]
19. New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene.
Mickisch GH; Merlino GT; Aiken PM; Gottesman MM; Pastan I
J Urol; 1991 Aug; 146(2):447-53. PubMed ID: 1677434
[TBL] [Abstract][Full Text] [Related]
20. Etoposide and ifosfamide for MP (melphalan and prednisolone)- and VAD (vincristine, adriamycin and dexamethasone)-resistant plasma cell myeloma: a case report.
Ikeda K; Abe N; Morioka A; Inoo M; Nagai M; Kubota Y; Irino S
Jpn J Med; 1990; 29(5):516-8. PubMed ID: 2089176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
